Combination of ‘Siddha’ drugs reduces anemia in adolescent girls: Study

The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme

Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial

Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients

Beiersdorf and Macro Biologics announce partnership to develop antimicrobial peptides

Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare

Royal Sense launches multiple products in pharmaceutical category

Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale

Shilpa Medicare receives USFDA approval for Bortezomib injection

Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)

Shilpa Medicare announces positive outcome of Phase 3 studies of NorUDCA

Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India

Novartis and Versant to form biotech venture Borealis Biosciences

Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company

FMD vaccination of pastoral sheep and goat to be extended pan India: Animal Husbandry Minister

Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP

This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers

Alembic receives USFDA final approval for Dabigatran Etexilate Capsules, 110 mg

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals